Diverging effects of tumor necrosis factor inhibitors and conventional synthetic disease-modifying antirheumatic drugs on immunosenescence and inflammageing in rheumatoid arthritis: a cross-sectional analysis
Whereas a TNFi treatment seems to counteract the non-inflammatory aspects of immunosenescence, it induces increasing proportions of terminally-differentiated, cytokine-producing effector memory T cells, requiring awareness as possibly contributing to secondary autoimmune phenomena in RA.
Authors
- Martina Prelog (ORCID: https://orcid.org/0000-0003-2034-2764)
- Tobias Schwarz (ORCID: https://orcid.org/0000-0001-8412-573X)
- Johannes Leierer (ORCID: https://orcid.org/0000-0002-7884-9827)
- Marc Schmalzing (ORCID: https://orcid.org/0000-0002-3289-2299)
- Giovanni Almanzar (ORCID: https://orcid.org/0000-0002-9430-7921)
- Martin Feuchtenberger (ORCID: https://orcid.org/0000-0001-8028-8099)
- Simon Völkl (ORCID: https://orcid.org/0000-0003-2193-3048)
- Friederike Deininger
- Christian A. Schmidt
- Hans‐Peter Tony
Institutions
- Innsbruck Medical University (AT)
- Universitätsmedizin Greifswald (DE)
- Universität Greifswald (DE)
- Universitätsklinikum Würzburg (DE)
- Medias Klinikum (DE)
Publication Details
- Journal
- Immunity & Ageing
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1186/s12979-025-00508-w
- Citations
- 1
- Primary Topic
- T-cell and B-cell Immunology
- Type
- article
- Field-Weighted Citation Impact
- 0.80